 |
|
Guillain-Barré Syndrome Following Influenza Vaccination
Penina Haber, MPH;
Frank DeStefano, MD, MPH;
Fredrick J. Angulo, DVM, PhD;
John Iskander, MD, MPH;
Sean V. Shadomy, DVM, MPH;
Eric Weintraub, MPH;
Robert T. Chen, MD, MA
JAMA. 2004;292:2478-2481.
Context An unexplained increase in the risk of Guillain-Barré syndrome (GBS) occurred among recipients of the swine influenza vaccine in 1976-1977. Guillain-Barré syndrome remains the most frequent neurological condition reported after influenza vaccination to the Vaccine Adverse Events Reporting System (VAERS) since its inception in 1990.
Objective To evaluate trends of reports to VAERS of GBS following influenza vaccination in adults.
Design, Setting, and Participants VAERS is the US national spontaneous reporting system for adverse events following vaccination. Reports of GBS in persons 18 years or older following influenza vaccination were evaluated for each influenza season from July 1, 1990, through June 30, 2003. The number of people vaccinated was estimated from the National Health Interview Survey and US census data. Beginning in 1994, active follow-up was conducted to verify GBS diagnosis and obtain other clinical details.
Main Outcome Measure Reporting rates of GBS following influenza vaccination over time.
Results From July 1990 through June 2003, VAERS received 501 reports of GBS following influenza vaccination in adults. The median onset interval (13 days) was longer than that of non-GBS reports of adverse events after influenza vaccine (1 day) (P<.001). The annual reporting rate decreased 4-fold from a high of 0.17 per 100 000 vaccinees in 1993-1994 to 0.04 in 2002-2003 (P<.001). A GBS diagnosis was confirmed in 82% of reports. Preceding illness within 4 weeks of vaccination was identified in 24% of reported cases.
Conclusions From 1990 to 2003, VAERS reporting rates of GBS after influenza vaccination decreased. The long onset interval and low prevalence of other preexisting illnesses are consistent with a possible causal association between GBS and influenza vaccine. These findings require additional research, which can lead to a fuller understanding of the causes of GBS and its possible relationship with influenza vaccine.
Author Affiliations: National Immunization Program, Centers for Disease Control and Prevention (Ms Haber, Drs DeStefano, Iskander, Shadomy, and Chen, and Mr Weintraub); and National Center for Infectious Diseases, Division of Bacterial and Mycotic Diseases (Dr Angulo), Atlanta, Ga.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Guillain-Barre Syndrome After Influenza Vaccination in Adults: A Population-Based Study.
Juurlink et al.
Arch Intern Med 2006;166:2217-2221.
ABSTRACT
| FULL TEXT
Safety of Trivalent Inactivated Influenza Vaccine in Children 6 to 23 Months Old
Hambidge et al.
JAMA 2006;296:1990-1997.
ABSTRACT
| FULL TEXT
No association between immunization and guillain-barre syndrome in the United kingdom, 1992 to 2000.
Hughes et al.
Arch Intern Med 2006;166:1301-1304.
ABSTRACT
| FULL TEXT
Neurologic Adverse Events Associated With Smallpox Vaccination in the United States, 2002-2004
Sejvar et al.
JAMA 2005;294:2744-2750.
ABSTRACT
| FULL TEXT
Legal Concerns and the Influenza Vaccine Shortage
Mello and Brennan
JAMA 2005;294:1817-1820.
FULL TEXT
Trends in Influenza Vaccination-Associated Guillain-Barre Syndrome
JWatch Pediatrics 2005;2005:14-14.
FULL TEXT
Trends in Influenza Vaccination-Associated Guillain-Barre Syndrome
JWatch Infect. Diseases 2004;2004:5-5.
FULL TEXT
|
